Pharmaceutical

Cidara to continue its CD388 influenza programme despite Janssen’s contrary decision

Janssen has plans to discontinue the CD388 influenza programme as part of pipeline prioritisation, but Cidara plans to continue development.

Jul 21, 2023 - 20:00
Cidara to continue its CD388 influenza programme despite Janssen’s contrary decision
Janssen has plans to discontinue the CD388 influenza programme as part of pipeline prioritisation, but Cidara plans to continue development.
Read the original article

Tags:

Previous Article

Idorsia sells off its Asia Pacific operations to raise funds

Next Article

Controlling the pharma machine: EMA conveys thoughts on AI use in industry

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: After late start, Eli Lilly has the momentum in battle for $30 billion weight loss market

STAT+: After late start, Eli Lilly has the momentum in ...

Jun 28, 2023

Itacitinib adipate by Incyte for Cytokine Release Syndr...

Oct 27, 2023

The White House has a pharmacy — and it was a mess, a new investigation found

The White House has a pharmacy — and it was a mess, a n...

Jan 24, 2024